Short Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Drops By 93.2%

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the target of a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 231,318 shares, a decrease of 93.2% from the July 15th total of 3,421,439 shares. Based on an average daily trading volume, of 665,888 shares, the days-to-cover ratio is presently 0.3 days. Approximately 20.0% of the company’s stock are short sold.

Calidi Biotherapeutics Stock Up 0.6%

Shares of CLDI stock traded up $0.01 on Tuesday, hitting $1.64. The stock had a trading volume of 231,099 shares, compared to its average volume of 230,617. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.15. Calidi Biotherapeutics has a one year low of $1.48 and a one year high of $96.95. The business has a 50 day moving average price of $2.19 and a 200 day moving average price of $5.46. The company has a market cap of $1.98 million, a PE ratio of -0.02 and a beta of 1.33.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its earnings results on Thursday, May 14th. The company reported ($6.88) EPS for the quarter.

Hedge Funds Weigh In On Calidi Biotherapeutics

A number of large investors have recently bought and sold shares of CLDI. Geode Capital Management LLC boosted its position in Calidi Biotherapeutics by 41.7% during the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after acquiring an additional 12,334 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Calidi Biotherapeutics in the 4th quarter worth $25,000. Finally, DRW Securities LLC bought a new position in shares of Calidi Biotherapeutics in the 4th quarter worth $173,000. Institutional investors own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.